Mira Pharmaceuticals (MIRA) Common Equity (2022 - 2025)

Mira Pharmaceuticals has disclosed Common Equity across 4 years of filings, most recently posting $10.4 million for Q4 2025.

• Common Equity for Q4 2025 came in at $10.4 million, up 372.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.4 million (up 372.34% YoY), and the FY2025 annual result was $10.4 million, up 372.34% from the prior year.
• Common Equity came in at $10.4 million for Q4 2025 at Mira Pharmaceuticals, up from $7.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $10.4 million in Q4 2025 to a low of -$1.8 million in Q1 2023.
• The 4-year median for Common Equity is $2.2 million (2024), against an average of $2.9 million.
• Across the five-year window, Common Equity surged 2432.48% in 2023 and tumbled 74.32% in 2025, its largest moves.
• Mira Pharmaceuticals' Common Equity stood at -$596232.0 in 2022, then soared by 833.67% to $4.4 million in 2023, then plunged by 49.71% to $2.2 million in 2024, then soared by 372.34% to $10.4 million in 2025.
• The last three Common Equity figures came in at $10.4 million (Q4 2025), $7.5 million (Q3 2025), and $569859.0 (Q2 2025), per Business Quant data.